Relief Therapeutics Holding SA (RLFTF)

1.3900 0.0000 (0.00%) At close: 10:29AM EDT

Relief Therapeutics Holding SA

Avenue de Secheron 15
Geneva 1202
Switzerland

https://www.relieftherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 49

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Michelle Lock	Interim CEO & Director	201.41k	N/A	1968
Mr. Paolo Galfetti	Chief Business Officer	303.13k	N/A	1965
Mr. Andrew J. Einhorn CPA	Chief Financial Officer	N/A	N/A	1960
Mr. Giorgio Reiner	Chief Scientific Officer	N/A	N/A	N/A
Mr. Vincenzo Gallo	Head of Legal & Compliance	N/A	N/A	N/A
Ms. Melinda Keegan	Chief Human Resources Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution, that is in Phase I clinical trial to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. Further, it is developing RLF-OD32, which is in Phase I clinical trial for the treatment of patients with phenylketonuria; and. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.

Corporate governance

Relief Therapeutics Holding SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.